- English (USA)
- English (UK)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
MDxHealth SA ADR (MDXH)
MDxHealth SA ADR stock price, this page displays NASDAQ MDXH stock exchange data. View the MDXH premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the MDxHealth SA ADR real time stock price chart below.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the MDXH quote. (ISIN: BE0974461940)
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the MDXH quote. (ISIN: BE0974461940)
3.410
-0.140(-3.94%)
Real-time Data·
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
3.385
3.610
52 wk Range
1.350
5.330
MDXH is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
3.3853.610
52 wk Range
1.3505.330
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
MDXH Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Sell
Analysts Sentiment
Strong Buy
Price Target
7.400
Upside
+117.01%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
High return over the last year
- Form 6K MDxHealth SA ADR For: 12 January
- Investing.com
- Form 6K MDxHealth SA ADR For: 26 February
- Investing.com
- Form 6K MDxHealth SA ADR For: 26 February
- Investing.com
- Form 6K MDxHealth SA For: 11 February
- Investing.com
- Form 13G MDxHealth SA For: 16 January
- Investing.com
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Strong Sell
MDxHealth ADR Company Profile
MDxHealth SA, a commercial-stage precision diagnostics company, provides urologic solutions in the United States, Europe, and internationally. The company’s testing solutions include Select mdx, a non-invasive urine test for prostate cancer that measures the expression of two mRNA cancer-related biomarkers; Confirm mdx for prostate cancer tissue test that validates epigenetic test that guides the detection of occult prostate cancer on a patient’s previously biopsied negative tissue; and Resolve mdx for urinary tract infection that identifies personalized effective antibiotic options against the patient’s infection. It also offers genomic prostate score, which provides personalized genomic insights to physicians and patients navigating the complexities of prostate cancer diagnosis and treatment. The company sells its products through urology sales force consisting of direct sales representatives, strategic account managers, and regional sales managers. The company has a collaboration with the University of Oxford: the initiation of Genomic Prostate Score (GPS) testing in the landmark UK ProtecT trial (Prostate Testing for Cancer and Treatment). The company was formerly known as OncoMethylome Sciences SA and changed its name to MDxHealth SA in October 2010. MDxHealth SA was incorporated in 2003 and is headquartered in Herstal, Belgium.
MDxHealth SA ADR Earnings Call Summary for Q4/2025
- MDxHealth Q4 EPS of -$0.17 missed estimates by 30.77%; revenue of $29.5M fell 2.61% short of $30.29M forecast despite 19% YoY growth.
- Liquid biopsy volumes surged 128% while tissue-based tests declined 5%; ExoDx acquisition integration drove operating expenses higher.
- Gross margin improved to 63.2% from 62.7% YoY; net loss widened to $8.9M from $6.8M due to acquisition-related costs.
- Company projects 2026 revenue of $137-140M, representing 28% YoY growth, driven by ExoDx contribution and liquid biopsy adoption.
- Stock held steady at $3.53 post-earnings; management emphasized operational efficiency focus and strategic value of expanding liquid biopsy portfolio.
Last Updated: 27-02-2026, 04:00 am
Read Full TranscriptCompare MDXH to Peers and Sector
Metrics to compare | MDXH | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipMDXHPeersSector | |
|---|---|---|---|---|
P/E Ratio | −5.6x | −0.4x | −0.6x | |
PEG Ratio | −0.10 | −0.03 | 0.00 | |
Price/Book | −21.1x | 7.1x | 2.6x | |
Price / LTM Sales | 1.7x | 10.9x | 3.3x | |
Upside (Analyst Target) | 97.2% | 1,745.6% | 44.5% | |
Fair Value Upside | Unlock | 1.9% | 5.2% | Unlock |
Analyst Ratings
6 Buy
0 Hold
0 Sell
Ratings:
6 analysts
Overall Consensus
Strong Buy
Analysts 12-Month Price Target:
Average 7.400
(+117.01% Upside)
Earnings
Latest Release
Feb 26, 2026
EPS / Forecast
-0.17 / -0.13
Revenue / Forecast
29.50M / 30.29M
FAQ
What Is the MDxHealth ADR (MDXH) Stock Price Today?
The MDxHealth ADR stock price today is 3.410.
What Stock Exchange Does MDxHealth ADR Trade On?
MDxHealth ADR is listed and trades on the Nasdaq Stock Exchange.
What Is the Stock Symbol for MDxHealth ADR?
The stock symbol for MDxHealth ADR is "MDXH."
What Is the MDxHealth ADR Market Cap?
As of today, MDxHealth ADR market cap is 182.340M.
What Is MDxHealth ADR's Earnings Per Share (TTM)?
The MDxHealth ADR EPS (TTM) is -0.639.
When Is the Next MDxHealth ADR Earnings Date?
MDxHealth ADR will release its next earnings report on 14-05-2026.
From a Technical Analysis Perspective, Is MDXH a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.
How Many Times Has MDxHealth ADR Stock Split?
MDxHealth ADR has split 1 times.
How Many Employees Does MDxHealth ADR Have?
MDxHealth ADR has 312 employees.
What is the current trading status of MDxHealth ADR (MDXH)?
As of 27-02-2026, MDxHealth ADR (MDXH) is trading at a price of 3.410, with a previous close of 3.550. The stock has fluctuated within a day range of 3.385 to 3.610, while its 52-week range spans from 1.350 to 5.330.
What Is MDxHealth ADR (MDXH) Price Target According to Analysts?
The average 12-month price target for MDxHealth ADR is USD7.400, with a high estimate of USD9 and a low estimate of USD6. 6 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +117.01% Upside potential.
What Is the MDXH Premarket Price?
MDXH's last pre-market stock price is 3.710. The pre-market share volume is 4,040.000, and the stock has decreased by 0.160, or 4.510%.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.